First investigation of the presence of *SPATE* genes in *Shigella* species isolated from children with diarrhea infection in Ahvaz, southwest Iran

This article was published in the following Dove Press journal:
Infection and Drug Resistance

Mojtaba Moosavian^{1,2}
Gholam Hossein Ghaderiyan²
Mojtaba Shahin²
Tahereh Navidifar²

¹Infectious and Tropical Diseases
Research Center, Health Research
Institute, Ahvaz Jundishapur University of
Medical Sciences, Ahvaz, Iran;

²Department of Microbiology, School of
Medicine, Ahvaz Jundishapur University
of Medical Sciences, Ahvaz, Iran

Background: *SPATE* (serine protease autotransporters of enterobacteriaceae) genes are considered as a group of the main virulence factors of *Shigella* species. This study aimed to investigate for the first time the distribution of *SPATE* genes among *Shigella* spp. isolated from children with diarrhea infection in Ahvaz, Iran.

Methodology: In this study, a total of 74 *Shigella* isolates were collected between August 2016 and June 2017 from feces of children with diarrhea and identified by biochemical and molecular methods for *Shigella* species. The frequency distribution of the *SPATE* genes, including *pic*, *pet*, *sat*, *sigA* and *sepA*, was evaluated using PCR. The genetic relationship of all isolates was evaluated by enterobacterial repetitive intergenic consensus-PCR.

Results: The most common species of *Shigella* was *S. flexneri*, followed by *S. sonnei* and *S. boydii*. In total, 95.94% of *Shigella* isolates had at least one of the *SPATE* genes. The presence of *pic*, *pet*, *sat*, *sigA* and *sepA* genes was confirmed among 35.13%, 27%, 47.29%, 58.1% and 39.18% of *Shigella* isolates, respectively. Of these *SPATE* genes, the *sat* and *sigA* genes were recognized as the most common autotransporters among *S. flexneri* and *S. sonnei* isolates, respectively. Also, either *S. flexneri* or *S. sonnei* isolates belonging to a same clone type had similar *SPATE* genes profile.

Conclusion: Our results revealed that the high distribution of *SPATE* genes among *Shigella* isolates in our region. Hence, this study highlights a need for epidemiological programs to monitor the distribution of *SPATE* genes locally for prevention from further dissemination of the *Shigella* isolates harboring them.

Keywords: *SPATE* genes, *Shigella* spp., PCR, antibiotic resistance

Introduction

Shigellosis is one of the main agents of diarrheal infections in developing countries especially among children <5 years of age. *Shigella* spp. isolates are the causative agents of 5–15% of all diarrheal infections worldwide¹ that have involved approximately 80–165 million cases, with over 600,000 deaths occurring each year.² The infection dose of *Shigella* spp. is as low as 10–100 organisms and over 80% of infections are due to person-to-person transmission.³ Shigellosis infection is associated with the colonization of four *Shigella* spp. – *S. dysenteriae*, *S. flexneri*, *S. boydii* and *S. sonnei* – that among them *S. flexneri* and *S. sonnei* are frequently isolated from Iran⁴ and other developing countries.⁵ Many reports have also demonstrated a relatively high prevalence of shigellosis among children with diarrheal infections.^{6–8}

Correspondence: Tahereh Navidifar
Department of Microbiology, School of
Medicine, Ahvaz Jundishapur University of
Medical Sciences, Golestan Street, Ahvaz,
Iran
Tel +98 930 729 2597
Email roya_67@gmail.com

The first step for the successful colonization of *Shigella* spp. in the intestine is the disruption of mucus integrity that can be facilitated by several virulence factors produced by *Shigella* spp. such as SPATE (serine protease autotransporters of enterobacteriaceae) genes.⁹ The SPATEs were first identified as autotransporters secreted by diarrheagenic *E. coli* and *Shigella*spp.; however, these genes are now detected in other members of the Enterobacteriaceae family. In *Shigella*spp., the SPATE genes were classified phylogenetically into two main classes, including the class I SPATEs that comprised of *Shigella* IgA-like protease homologue (*sigA*), secreted autotransporter toxin (*sat*) and plasmid-encoded toxin (*pet*) which are directly cytotoxic for epithelial cells, as well as the class 2 SPATEs, including *Shigella* extracellular protein A (*sepA*) and protease involved in intestinal colonization (*pic*), which facilitate the intestinal inflammation and colonization. Overall, *Shigella* isolates harboring these genes are able to induce the inflammation and extensive mucosal damages in intestinal infections, especially when these isolates encode more than one the SPATE gene.¹⁰ Hence, the understanding of the distribution of SPATE genes in *Shigella* isolates in the epidemiologic and local researches can be useful gene targets for other researchers who are designing new antimicrobial therapies against them.

The aim of this study was to investigate for the first time the presence of the genes encoding SPATEs among clinical isolates of *Shigella*spp. from children with diarrheal infection in Ahvaz, southwest, Iran.

Materials and methods

The collection of samples

We collected 3,254 stool culture of children <16 years of age with diarrheal infections referred to Golestan and Abuzar Hospitals during a period of 10 months from August 2016 to June 2017. The study design was approved by the Research Ethics Committee of Ahvaz Jundishapur University of Medical Sciences, Iran (IR.AJUMS.REC.1395.427). These samples were inoculated into Gram-negative (GN) Broth tubes as an enrichment medium as a part of the routine hospital laboratory procedure and then immediately transferred to the Laboratory of Microbiology Department of Medicine School of Ahvaz, Iran. From each patient, only one *Shigella* isolate in the diarrheal phase was included in this study. The GN Broth tubes were incubated at 37°C for 4–6 hrs and then streaked on Xylose Lysine

Deoxycholate Agar and Eosin Methylene Blue Agar (Merck-Germany). All plates were incubated at 37°C for 24–48 hrs. The suspected colonies were biochemically identified as *Shigella*spp. using Lysine Decarboxylase Agar, Sulfide-indole-motility, Triple-sugar iron Agar, Urea Agar and Simmons citrate Agar (Merck-Germany).¹¹

Antimicrobial susceptibility testing

Determination of antimicrobial susceptibility was performed by Kirby-Bauer-disc diffusion method according to the guidelines of the Clinical and Laboratory Standards Institute.¹³ The antibiotic discs used were ceftriaxone (CRO; 30 µg), ciprofloxacin (CIP; 5 µg), trimethoprim/sulfamethoxazole (SXT; 1.25/23.75 µg), nalidixic acid (NA; 30 µg), amikacin (AK; 30 µg), gentamycin (GM; 10 µg), ceftazidime (CAZ; 30 µg) and tetracycline (TE; 30 µg). All of these plates were incubated for an overnight at 35°C and the clear zones of bacterial growth inhibition were measured with an accuracy of ±0.1 mm.¹²

DNA extraction

The whole genome DNA was extracted using boiling method as described previously.¹³

Multiplex PCR assay for molecular identification of *Shigella* spp

The Tetraplex PCR assay was setup using whole genome DNA of the reference *Shigella* strains, including *S. flexneri* ATCC 12022, *S. sonnei* ATCC 9290, *S. boydii* ATCC 9207 and *S. dysenteriae* PTCC 1188 as the positive control strains along with water as the negative control. A multiplex PCR reaction was prepared in the final volume of 25 µL, including 1 U of AmpliTaq DNA polymerase, 2 µL of genomic DNA, 1X PCR buffer, 1.5 mM MgCl₂, 200 µM dNTPs and distilled water up to the final volume of 25 µL. In this study, all primers were synthesized by Cinna gene Company, Iran. The primer concentrations were as follows: 0.2 Pmol/µL of primers SflexDF1 and SflexDR1; 0.35 Pmol/µL of primers SsonDF1 and SsonDR1; 0.15 Pmol/µL of primers SdysDF1 and SdysDR1; and 0.4 Pmol/µL of primers SboyDF1 and SboyDR1. The sequences and sizes of the primers are shown in Table 1.^{14,15} The amplification process was performed in Mastercycler Nexus Thermal Cycler Gradient (Eppendorf, Hamburg, Germany) with one cycle of initial denaturation at 94°C for 5 mins, followed by 35 cycles of 30 s at 94°C, 30 s at 55°C and 60 s at 72°C, with a final

Table 1 Primers used for identifying each species with their sequences sizes

Name	Primer sequence (5' to 3')	Length	Target gene	Target identity	Ref
SflexDFI SflexDRI	F- TTT ATG GCT TCT TTG TCG GC R-CTG CGT GAT CCG ACC ATG	570 bp	<i>rfc</i>	<i>S. flexneri</i>	14
SsonDFI SsonDRI	F-TCT GAA TAT GCC CTC TAC GCT R-GAC AGA GCC CGA AGA ACC G	430 bp	<i>wbgZ</i>	<i>S. sonnei</i>	14
SdysDFI SdysDRI	F-TCT CAA TAA TAG GGA ACA CAG C R-CAT AAA TCA CCA GCA AGG TT	211 bp	<i>rfpB</i>	<i>S. dysenteriae</i>	14
SboyDFI SboyDRI	F- GAGCA CGGAA ACAGA GAGCGCC R- GGTGC GTTCT TCCGG TGTTG TG	240bp	Hypothetical protein	<i>S. boydii</i>	15
SgenDFI SgenDRI	F- TGC CCA GTT TCT TCA TAC GC R- GAA AGTAGCTCC CGAAATGC	870 bp	<i>invC</i>	<i>Shigella</i> genus	14

extension for 7 mins at 72°C.¹⁵ All PCR products were electrophoresed on 1% agarose gel stained with ethidium bromide and their images were visualized by Gel Documentation (Vilber Company, Germany).

Amplification of SPATE genes

The amplifications of SPATEs including the *pet*, *sat*, *pic*, *sigA* and *sepA* genes were performed on the whole genome, as previously described.¹⁰ All reactions were established using the primers and PCR conditions described in Table 2. The PCR products were electrophoresed on 1% agarose gel stained with ethidium bromide and their images were visualized by Gel Documentation (Vilber Company, Germany).

ERIC-PCR typing and analysis

The genetic relationship of *S. flexneri* and *S. sonnei* isolates was evaluated by the enterobacterial repetitive intergenic

consensus-PCR (ERIC-PCR) using primers of ERIC-F (5'-ATGTAAGCTCCTGGGGATTAC-3') and ERIC-R (5'-AAGTAAGTGACTGGGGTGA GCG-3').¹⁶ The PCR reaction was performed in the final volume of 20 µL as follows: 1U Taq DNA polymerase, 1.5 mM MgCl₂, 200 µM dNTPs, 0.20 µM of each primer, 10x PCR buffer, 3 µL of template DNA and distilled water up to a final volume of 20 µL. The amplification process was performed in Mastercycler Nexus Thermal Cycler Gradient (Eppendorf, Hamburg, Germany) with one cycle of initial denaturation at 94°C for 5 mins, followed by 35 cycles of denaturation at 94°C for 60 s, annealing at 55°C for 60 s, extension at 72°C for 90 s, with a cycle of final extension at 72°C for 10 mins. The amplified products were resolved on agarose gel 1.5%, stained with ethidium bromide 0.5 µg/mL. The data analyses were performed using the Gel Compare II software version 6.6 (Applied Math, Sint-Martens-Latem, Belgium). The

Table 2 Primer used for the amplifications of qnr determinants and SPATE genes

Gene	Primer sequence (5' to 3')	bp	Condition PCR	Ref
<i>pic</i>	F- ACTGGATCTTAAGGCTCAGGAT R-GACTTAATGTCACTGTTTCAGCG	572	94°C, 15 mins; 94°C, 30 s; 58°C, 45 s; 72°C, 45 s (35 cycles)	11
<i>pet</i>	F- GGCACAGAATAAAGGGGTGTTT R-CCTCTTGTTTCCACGACATAC	302		
<i>sepA</i>	F- GCAGTGGAAATATGATGCGGC R-TTGTTTCAGATCGGAGAAGAACG	794		
<i>sigA</i>	F- CCGACTTCTCACTTTCTCCCG R-CCATCCAGCTGCATAGTGTG	430		
<i>sat</i>	F- TCAGAAGCTCAGCGAATCATTG R-CCATTATCACCAGTAAAACGCACC	930	94°C, 15 mins; 94°C, 30 s; 59°C, 45 s; 72°C, 45 s (35 cycles)	

similarity pattern was calculated using the Unweighted-Pair Group Method/the Dice similarity coefficient with a position tolerance of 1.5%. Isolates with more than 90% similarity were considered as clonal type.

Statistical analysis

The descriptive statistic tests were performed in SPSS version 16.00.

Results

Identification of *Shigella* spp. and determination of antibiotic susceptibility

In our study, of 3,254 stool samples, 74 (2.27%) were positive for *Shigella* species using bacterial culture. Of those, 736 samples (22.6%) belong to children <2 years of age, 435 (13.4%) samples in the age group between 2 and 5 years, 1,095 (33.6%) samples in the age group between 6 and 10 years and 988 (30.36%) samples in the age group between 11 and 15 years. According to PCR results, the most common *Shigella* species was *S. flexneri* (36 isolates; 48.6%), followed by *S. sonnei* (33 isolates; 46.6%) and *S. boydii* (five isolates; 6.7%). The distribution of *Shigella* spp. isolates in different age groups is shown in Table 3. According to our study findings, both *S. sonnei* and *S. flexneri* were more prevalent in the age group of 6–10 years of age than other groups.

The results of antibiotic susceptibility assay demonstrated that the majority of these isolates were resistant to trimethoprim/sulfamethoxazole (87.8%) and tetracycline (67.6%), followed by ceftriaxone (51.5%), nalidixic acid (28.4%) and ceftazidime (20.3%). However, the rates of resistance

to gentamycin (2.7%), amikacin (2.7%) and ciprofloxacin (6.7%) were low. The frequency rates of antibiotic resistance of all strains are shown in Table 4. According to these results, all *S. boydii* strains were resistant to TMP-SXT.

Frequency of class 1 and 2 SPATEs

We screened the presence of class 1 and 2 SPATEs among *Shigella* spp. (Table 5). Moreover, among 36 *S. flexneri* isolates, 12 (33.33%) harbored only class 1 and 24 (66.66%) harbored both of class 1 and 2 SPATE genes while any strain did not harbor only class 2 SPATEs. On the other hand, of 33 *S. sonnei* isolates, 11 (33.33%) harbored only class 1, 2 (6.06%) harbored only class 2 and 19 (57.57%) harbored both of class 1 and 2 SPATE genes, while only one *S. sonnei* strain harbored neither of class 1 nor class 2 SPATEs. Also, of five *S. boydii* strains, only one strain harbored the *sigA* gene, one harbored the *sepA* gene and one harbored both the *sigA* and *sepA* genes.

Of 36 *S. flexneri* isolates, the genes encoding *pet*, *sat*, *sigA*, *sepA* and *pic* were detected among 7 (19.44%), 27 (75%), 25 (69.44%), 13 (36.11%) and 14 (38.88%) isolates, respectively. Also, of 33 *S. sonnei* isolates, the genes encoding *pet*, *sat*, *sigA*, *sepA* and *pic* were detected among as well as 13 (39.39%), 8 (24.24%), 17 (51.51%), 14 (42.42%) and 12 (36.36%), respectively.

Genetic diversity of *S. flexneri* and *S. sonnei* isolates

In our study, 36 *S. flexneri* isolates were categorized into 7 clone types and 8 single types using ERIC-PCR (Figure 1A).

Table 3 Distribution of *Shigella* spp. isolates in different age groups

Age groups	<24 months N=736 (%)	2–5 years N=435(%)	6–10 years N=1095(%)	11 to <15 years N=988(%)
<i>S. flexneri</i> N=36	0	5 (13.8)	19 (52.7)	12 (33.33)
<i>S. sonnei</i> N=33	0	1 (3.03)	22 (66.6)	10 (30.3)
<i>S. boydii</i> N=5	0	0	4 (80)	1 (20)

Table 4 The distribution pattern of antibiotic resistance based on species

Antibiotic	AK n (%)	GM n (%)	CIP n (%)	NA n (%)	CAZ n (%)	CRO n (%)	TMP –SXT n (%)	TET n=(%)
<i>S. flexneri</i> N=36	1 (2.7)	1 (2.7)	4 (11.11)	16 (44.44)	9 (25)	20(55.5)	32(88.80)	27(75)
<i>S. sonnei</i> N=33	1 (3.03)	1 (3.03)	1 (3.03)	4 (12.12)	5 (27.27)	16(48.4)	21(63.60)	28(84.84)
<i>S. boydii</i> N=5	0	0	0	1 (20)	1 (20)	2(40)	5(100)	3(60)

Abbreviations: AK, amikacin; GM, gentamycin; CIP, ciprofloxacin; NA, nalidixic acid; CAZ, ceftazidime; TMP-SMX, trimethoprim/sulfamethoxazole; CRO, ceftriaxone; TET, tetracycline.

Table 5 Distribution of the SPATE genes in *Shigella* isolates

Species	Strain	Class 1			Class 2	
		Pet	sat	sigA	sepA	pic
<i>S. flexneri</i>	SF01	-	+	+	-	-
	SF02	+	+	+	-	+
	SF03	-	+	-	+	+
	SF04	-	+	+	+	+
	SF05	-	+	+	+	-
	SF06	+	-	-	-	-
	SF07	-	+	-	-	-
	SF08	-	+	+	-	+
	SF09	-	+	+	-	+
	SF10	-	-	+	-	-
	SF11	+	+	+	+	-
	SF12	-	+	-	+	-
	SF13	-	+	-	+	+
	SF14	-	+	+	-	+
	SF15	-	+	-	-	+
	SF16	+	-	-	-	-
	SF17	-	+	+	-	-
	SF18	-	+	+	+	-
	SF19	-	+	+	-	+
	SF20	-	+	-	-	-
	SF21	-	+	+	-	+
	SF22	-	+	+	+	-
	SF23	+	-	+	-	-
	SF24	-	-	+	-	-
	SF25	-	+	+	-	+
	SF26	-	+	-	+	-
	SF27	-	+	+	+	-
	SF28	-	-	+	-	-
	SF29	+	-	+	-	+
	SF30	-	+	+	+	+
	SF31	-	+	+	-	-
	SF32	-	-	+	-	-
	SF33	-	+	-	-	-
	SF34	-	+	+	+	-
	SF35	+	-	+	+	+
	SF36	-	+	-	-	-
	Total	7	27	25	13	14
<i>S. sonnei</i>	SN01	-	-	-	+	-
	SN02	+	+	-	-	+
	SN03	+	-	+	+	+
	SN04	-	-	+	+	+
	SN05	+	-	+	-	-
	SN06	-	-	-	-	-
	SN07	+	-	-	+	+
	SN08	+	-	-	+	-
	SN09	-	+	-	-	+
	SN10	+	-	-	-	-
<i>S. sonnei</i>	SN11	+	+	+	-	-
	SN12	-	-	+	+	+
	SN13	+	-	-	+	-
	SN14	-	+	-	-	-
	SN15	-	-	+	-	+

(Continued)

Table 5 (Continued).

Species	Strain	Class 1			Class 2	
		Pet	sat	sigA	sepA	pic
	SN16	-	-	+	-	-
	SN17	-	-	+	+	-
	SN18	-	-	-	+	-
	SN19	-	-	+	-	-
	SN20	-	-	+	-	-
	SN21	+	-	+	-	-
	SN22	-	-	+	+	+
	SN23	-	+	-	+	-
	SN24	-	-	+	-	-
	SN25	-	+	-	-	+
	SN26	+	-	-	+	+
	SN27	+	-	+	-	+
	SN28	+	-	+	-	-
	SN29	-	-	+	-	-
	SN30	-	+	+	+	+
	SN31	-	+	-	+	-
	SN32	-	-	-	-	-
	SN33	+	-	-	-	-
	Total	13	8	17	14	12
<i>S. boydii</i>	SB01	-	-	+	-	-
	SB02	-	-	-	+	-
	SB03	-	-	+	+	-
	SB04	-	-	-	-	-
	SB05	-	-	-	-	-
	Total	0	0	2	2	0

Abbreviations: SF, *S. flexneri*; SS, *S. sonnei*; SB, *S. boydii*.

Also, 33 *S. sonnei* isolates were clustered into 10 clone types and 3 single types (Figure 1B). According to the results demonstrated in Figure 1 and Table 5, either *S. flexneri* or *S. sonnei* isolates belonging to a same clone type had similar SPATE genes profile.

Discussion

The local epidemiology of *Shigella* spp. is changing over time.¹⁷ In our study, the prevalence rate of *Shigella* spp. in diarrheal infection was 2.27% and *S. flexneri* was recognized as the dominant species. In consistent with our results, in a previous study in our region by Jomezadeh et al¹⁸ during June 2011–May 2013, *S. flexneri* was the most common *Shigella* spp. among the pediatric age group. However, the frequency rate of *Shigella* spp. in their study was higher than our study (5.1% vs 2.27%) that may reflect the increasing hygiene levels in our region than that reported by Jomezadeh et al. Nevertheless, the frequency rate of *Shigella* spp. in our study was higher than

Figure 1 Dendrograms of 36 *S. flexneri* isolates (A) and 33 *S. sonnei* (B) isolates by ERIC-PCR fingerprinting.

Abbreviations: SF, *S. flexneri*; SN, *S. sonnei*; CT, clonal type; ST, single type; A, Abuzar Hospital; B, Golestan Hospital.

those reported in other reports,^{19,20} but was comparable to a previous study in Iran.¹⁷

According to data obtained from most researches conducted in Iran, *S. flexneri* was diagnosed as the main agent of shigellosis^{17,18,21,22} whereas in a few studies, *S. sonnei* has been found as the dominant species.^{4,23} In our study, the frequency of *S. flexneri* (36 isolates) was relatively similar to *S. sonnei* (33 isolates), indicating that *S. flexneri* may be replaced locally with *S. sonnei*. We also found a few *S. boydii* isolates which was in accordance with some other studies conducted in Iran,^{4,17,18,20,21} however, in the research conducted by Mashoof et al in Tabriz,²⁴ *S. sonnei* had the lowest frequency. *S. boydii* was first detected in India and is still relatively prevalent in Indian subcontinent.²⁵ However, many researchers in other regions of the world have reported the lower frequencies of *S. boydii* than India subcontinent.^{26–30}

In this study, most isolates were resistant to TMP-SXT and tetracycline (more than 67%) that are in agreement with other studies reported in Iran and some other countries.^{17,18,21,25,31} In our study, *S. flexneri* isolates were more resistant to TMP-SXT than *S. sonnei* (88.9% vs 63.6%; $p > 0.05$). TMP-SXT and tetracycline were previously used as two first-line antibiotics for the treatment of bacterial diarrheas such as shigellosis.³² However, because of the increasing prevalence of tetracycline or TMP-SXT-resistant *Shigella* strains, the use of these antibiotics is only limited to some regions where the resistance rates still are low.³⁰

In this study, the resistance to gentamicin and amikacin was much low, as reported in other studies by Orrett et al³⁰ in Trinidad and Peirano et al³³ in Brazil. Overall, *Shigella* spp. isolates are usually susceptible to aminoglycoside agents in vitro, but these agents are ineffective in vivo,^{14,34} hence do not recommend for shigellosis treatment.

The results of our study implied that the resistance rate to ciprofloxacin was much low. In contrast to our results, Jomezadeh et al,¹⁸ Hosseini Naveh et al,²¹ Özmert et al³⁵ and Ghosh et al²⁵ documented a relatively high prevalence of resistance to ciprofloxacin and nalidixic acid among *Shigella* isolates. It is suggested that the cross-resistance to nalidixic acid or/and the excessive use of these antibiotics may have been contributed to the high prevalence of fluoroquinolone-resistant isolates.³⁴

The SPATE genes as an expanding family of secreted autotransporters in GN bacteria have various functions such as protease or mucinase that directly or indirectly can be toxic for the intestine cells.³⁶ There is limited available information

on the distribution of the SPATE genes in *Shigella* isolates, so that more research is needed to fully understand the distribution of these genes among *Shigella* spp. isolates. In this current study, the distribution of five SPATE genes was determined by PCR. According to our data, most *S. flexneri* and *S. sonnei* isolates harbored two or more than two SPATE genes, as described in other studies by Hosseini Naveh et al³⁷ and Boisen et al¹⁰. Moreover, Hosseini Naveh et al³⁷ in Iran showed that 11 of 31 *S. flexneri* isolates and 6 of 7 *S. boydii* isolates were positive for four SPATE genes. According to the evidences obtained from the study of Boisen et al,¹⁰ the numbers of SPATE genes in the bacterial pathogens had the direct relationship with the virulence of the organisms and subsequently the severity of tissue damages. Also, these researchers showed that *Shigella* isolates commonly had encoded more than one SPATE gene rather than diarrheal *E. coli* pathotypes (EAEC, EIAC, ETEC, DAEC and EPEC), therefore, clinically, *Shigella* spp. are more virulent than *E. coli* pathotypes.¹⁰

In this study, the *sat* gene was recognized as the most common SPATE gene among *S. flexneri* isolates. In agreement with our study, Hosseini Naveh et al, Fan et al and Ruiz et al found the high rates of this gene among *S. flexneri* rather than other *Shigella* species.^{37,38,39} The *sat* gene was first studied in uropathogenic *E. coli* strains;³⁶ however, recently several studies showed the presence of this gene in the Enterotoxigenic *Escherichia coli* clinical strains.^{40,41} The in vitro experiments indicated that *sat* can induce the cytoskeletal derangement in intestinal epithelium directly although cleaving spectrin proteins.⁴²

We also showed a high prevalence of the *sigA* gene among both *S. flexneri* (24 of 36) and *S. sonnei* (17 of 31) isolates. In consistent with our results, Hosseini Naveh et al³⁷ showed the presence of the *sigA* gene among all *S. sonnei* isolates while in contrast to our results, they detected a relatively low frequency of this gene in *S. flexneri* isolates. Also, Fan et al³⁸ showed a high frequency of the *sigA* gene in the majority of *S. flexneri* serotypes. The *sigA* gene was initially reported as a part of chromosomal pathogenicity island in a *S. flexneri* clinical strain.³⁵ Later, studies on the action mechanism of this gene by Al-Hasani et al⁴³ revealed that the *sigA* gene induced the fluid accumulation in intestine and cleaved intracellular fodrin (an analog of spectrin) in situ that resulted in the derangement of the cytoskeleton during the pathogenesis of shigellosis.⁴³ In addition *Shigella* isolates, some other studies indicated the high distribution of the *sigA* gene in Enteroinvasive *Escherichia coli* (EIEC)^{10,44} than other pathotypes of

E. coli.^{40,41} Moreover, Boisen et al¹⁰ found that six of ten EIEC isolates were positive for the amplification of the *sigA* gene as only the SPATE gene, suggesting that *sigA* may play an important role in the pathogenesis of EIEC, as well as *Shigella* isolates.

We indicated that class 2 SPATE genes (*sepA* and *pic*) were relatively common among *Shigella* isolates: 35.13% of the isolates were positive for the *pic* gene and 39.18% were positive for the *sepA* gene. Moreover, the frequency rates of the class 2 SPATE genes were relatively similar in *S. flexneri* and *S. sonnei* strains. In agreement with our results, Fan et al³⁸ and Boisen et al¹⁰ showed the distribution of the class 2 SPATEs in different serotypes of *S. flexneri*, as well as Hosseini Naveh et al³⁷ in Iran that reported the presence of the class 2 SPATE genes in both *S. flexneri* and *S. boydii* isolates.

pic initially was reported in a clinical strain of *S. flexneri* 2a, mediates the serum resistance through the degradation of one of the components of the complement system along with a mucinase activity, resulting in the successful intestinal colonization of *Shigella* isolates.

sepA also was originally described in *S. flexneri* 2a, induces the intestinal inflammation together with the fluid accumulation and mucosal atrophy by an unknown mechanism.³⁶

In our study, *S. boydii* isolates had the low rates of SPATE genes (*sepA* and *sigA*) that is in contrast to findings of Hosseini Naveh et al³⁷ in Iran who reported the high frequencies of the SPATE genes except to the *sat* gene among *S. boydii* isolates.

Molecular typing methods are used to establish the clonal relationships between isolates and confirm the clinical or epidemiological data, as well as the spread of an infectious agent in community.⁴⁵ ERIC-PCR is a rapid and low-cost method that has differentiated closely related strains of bacteria from each other.⁴⁶ In this present study, *S. flexneri* and *S. sonnei* isolates were clustered in 7 clonal types and 10 clonal types, respectively. Also, either *S. flexneri* or *S. sonnei* isolates belonging to a same clone type had similar SPATE genes profile, indicating that ERIC-PCR has high discriminatory power.

Conclusion

In this current study, we showed that the frequency rates of *S. flexneri* and *S. sonnei* were relatively similar. Also, we indicated the high distribution of the SPATE genes among *Shigella* isolates especially in *S. flexneri*. Hence, this study

highlights a need for the epidemiological programs to monitor the distribution of SPATE genes locally for prevention from further dissemination of the *Shigella* isolates harboring them.

Acknowledgments

This study was a part of the M. Sc. thesis of Gholam Hossein Ghaderiyan, which obtained research approval from and was financially supported by the vice chancellor of Research Affairs of Infectious and Tropical Diseases Research Center, Health Research Institute, Jundishapur University of Medical Sciences, Ahvaz, Iran (Grant No. OG-95120). The authors also thank Doctor Haghighi of Bushehr University of Medical Sciences, for the donation of reference *Shigella* strains.

Disclosure

The authors report no conflict of interests in this work.

References

- Schroeder GN, Hilbi H. Molecular pathogenesis of *Shigella* spp.: controlling host cell signaling, invasion, and death by type III secretion. *Clin Microbiol Rev*. 2008;21(1):134–156. doi:10.1128/CMR.00032-07
- Kweon MN. Shigellosis: the current status of vaccine development. *Curr Opin Infect Dis*. 2008;21(3):313–318. doi:10.1097/QCO.0b013e3282f88b92
- Gupta A, Polyak CS, Bishop RD, Sobel J, Mintz ED. Laboratory-confirmed shigellosis in the United States, 1989–2002: epidemiologic trends and patterns. *Clin Infect Dis*. 2004;38(10):1372–1377. doi:10.1086/386326
- Ranjbar R, Soltan Dallal MM, Talebi M, Pourshafie MR. Increased isolation and characterization of *Shigella sonnei* obtained from hospitalized children in Tehran, Iran. *J Health Popul Nutr*. 2008;26(4):426–430.
- Niyogi SK. Increasing antimicrobial resistance—an emerging problem in the treatment of shigellosis. *Clin Microbiol Infect*. 2007;13(12):1141–1143. doi:10.1111/j.1469-0691.2007.01829.x
- Centers for Disease Control and Prevention (CDC). National Shigella Surveillance Annual Report, 2012. Atlanta: US Department of Health and Human Services; CDC; 2014.
- European Centre for Disease Prevention and Control. *Annual Epidemiological Report Reporting on 2011 Surveillance Data and 2012 Epidemic Intelligence Data*. Stockholm: ECDC; 2013.
- von Seidlein L, Kim DR, Ali M, et al. A multicentre study of *Shigella* diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. *PLoS Med*. 2006;3(9):e353. doi:10.1371/journal.pmed.0030353
- Mattock E, Blocker AJ. How do the virulence factors of shigella work together to cause disease? *Front Cell Infect Microbiol*. 2017;7:64. doi:10.3389/fcimb.2017.00517
- Boisen N, Ruiz-Perez F, Scheutz F, Krogfelt KA, Nataro JP. Short report: high prevalence of serine protease autotransporter cytotoxins among strains of enteroaggregative *Escherichia coli*. *Am J Trop Med Hyg*. 2009;80(2):294–301.
- Walker KE, Homeman AJ, Mahon CJ, et al. Enterobacteriaceae. In: Mahon CR, Lehman DC, Manuselis G, editors. *Textbook of Diagnostic Microbiology*. Maryland Heights, Mo: Saunders/Elsevier; 2011:427–470.

12. CLSI. M100-S28. Performance Standards for Antimicrobial Susceptibility Testing. Twenty-eight informational supplement M100. Wayne: Clinical and Laboratory Standards Institute; 2018.
13. Li P, Niu W, Li H, et al. Rapid detection of *Acinetobacter baumannii* and molecular epidemiology of carbapenem-resistant *A. baumannii* in two comprehensive hospitals of Beijing, China. *Front Microbiol*. 2015;6:997. doi:10.3389/fmicb.2015.00997
14. Ojha SC, Yean Yean C, Ismail A, Singh KK. A pentaplex PCR assay for the detection and differentiation of *Shigella* species. *Biomed Res Int*. 2013;2013:412370. doi:10.1155/2013/412370
15. Kim HJ, Ryu JO, Song JY, Kim HY. Multiplex polymerase chain reaction for identification of *Shigellae* and four *Shigella* species using novel genetic markers screened by comparative genomics. *Foodborne Pathog Dis*. 2017;14(7):400–406. doi:10.1089/fpd.2016.2221
16. Kosek M, Yori PP, Gilman RH, et al. Facilitated molecular typing of *Shigella* isolates using ERIC-PCR. *Am J Trop Med Hyg*. 2012;86(6):1018–1025. doi:10.4269/ajtmh.2012.11-0671
17. Pourakbari B, Mamishi S, Mashoori N, et al. Frequency and antimicrobial susceptibility of *Shigella* species isolated in Children Medical Center Hospital, Tehran, Iran, 2001–2006. *Braz J Infect Dis*. 2010;14(2):153–157.
18. Jomezadeh N, Babamoradi S, Kalantar E, Javaherizadeh H. Isolation and antibiotic susceptibility of *Shigella* species from stool samples among hospitalized children in Abadan, Iran. *Gastroenterol Hepatol Bed Bench*. 2014;7(4):218–223.
19. Urvashi SS, Dutta R. Antimicrobial resistance pattern of *Shigella* species over five years at a tertiary-care teaching hospital in north India. *J Health Popul Nutr*. 2011;29(3):292–295.
20. Ashkenazi S, Levy I, Kazaronovski V, Samra Z. Growing antimicrobial resistance of *Shigella* isolates. *J Antimicrob Chemother*. 2003;51(2):427–429.
21. Hosseini Nave H, Mansouri S, Sadeghi A, Moradi M. Molecular diagnosis and anti-microbial resistance patterns among *Shigella* spp. isolated from patients with diarrhea. *Gastroenterol Hepatol Bed Bench*. 2016;9(3):205–210.
22. Jafari F, Garcia-Gil LJ, Salmanzadeh-Ahrabi S, et al. Diagnosis and prevalence of enteropathogenic bacteria in children less than 5 years of age with acute diarrhea in Tehran children's hospitals. *J Infect*. 2009;58(1):21–27. doi:10.1016/j.jinf.2008.10.013
23. Farshad S, Sheikhi R, Japoni A, Basiri E, Alborzi A. Characterization of *Shigella* strains in Iran by plasmid profile analysis and PCR amplification of *ipa* genes. *J Clin Microbiol*. 2006;44:2879–2883. doi:10.1128/JCM.00310-06
24. Mashouf RY, Moshtaghi AA, Hashemi SH. Epidemiology of *Shigella* species isolated from diarrheal children and drawing their antibiotic resistance pattern. *Iran J Clin Infect Dis*. 2006;1(3):149–155.
25. Ghosh S, Pazhani GP, Niyogi SK, Nataro JP, Ramamurthy T. Genetic characterization of *Shigella* spp. isolated from diarrhoeal and asymptomatic children. *J Med Microbiol*. 2014;63(pt7):903–910. doi:10.1099/jmm.0.070912-0
26. Mache A. Antibiotic resistance and Sero-groups of *Shigella* among pediatric outpatients in Southwest Ethiopia. *East Afr Med J*. 2001;78(6):296–299.
27. Abu-Elyazeed RR, Wierzb TF, Frenck RW, et al. Epidemiology of *Shigella*-associated diarrhea in rural Egyptian children. *Am J Trop Med Hyg*. 2004;71(3):367–372.
28. Zafar A, Hasan R, Nizami SQ, et al. Frequency of isolation of various subtypes and antimicrobial resistance of *Shigella* from urban slums of Karachi, Pakistan. *Int J Infect Dis*. 2009;13(6):668–672. doi:10.1016/j.ijid.2008.10.005
29. Khan S, Singh P, Asthana A, Ansari M. Magnitude of drug resistant shigellosis in Nepalese patients. *Iran J Microbiol*. 2013;5(4):334–338.
30. Orrett FA. Prevalence of *Shigella* serogroups and their antimicrobial resistance patterns in southern Trinidad. *J Health Popul Nutr*. 2008;26(4):456–462.
31. Bhattacharya D, Sugunan AP, Bhattacharjee H, et al. Antimicrobial resistance in *Shigella*—rapid increase & widening of spectrum in Andaman Islands, India. *Indian J Med Res*. 2012;135:365–370.
32. Erdman SM, Buckner EE, Hindler JF. Options for treating resistant *Shigella* species infections in children. *J Pediatr Pharmacol Ther*. 2008;13(1):29–43. doi:10.5863/1551-6776-13.1.29
33. Peirano G, Souza FS, Rodrigues DP; *Shigella* Study Group. Frequency of serovars and antimicrobial resistance in *Shigella* spp. from Brazil. *Mem Inst Oswaldo Cruz*. 2006;101(3):245–250.
34. World Health Organization. *Guidelines for the Control of Shigellosis, Including Epidemics Due to Shigella Dysenteriae Type 1*. Geneva, Switzerland: World Health Organization Press; 2005.
35. Özmert EN, İnce OT, Örün E, Yalçın S, Yurdakök K, Gür D. Clinical characteristics and antibiotic resistance of *Shigella* gastroenteritis in Ankara, Turkey between 2003 and 2009, and comparison with previous reports. *Int J Infect Dis*. 2011;15(12):e849–e53. doi:10.1016/j.ijid.2011.08.008
36. Dautin N. Serine protease autotransporters of enterobacteriaceae (SPATEs): biogenesis and function. *Toxins (Basel)*. 2010;2(6):1179–1206. doi:10.3390/toxins2061179
37. Hosseini Nave H, Mansouri S, Emaneini M, Moradi M. Distribution of genes encoding virulence factors and molecular analysis of *Shigella* spp. isolated from patients with diarrhea in Kerman, Iran. *Microb Pathog*. 2016;92:68–71. doi:10.1016/j.micpath.2015.11.015
38. Fan W, Qian H, Shang W, et al. Low distribution of genes encoding virulence factors in *Shigella flexneri* serotypes 1b clinical isolates from eastern Chinese populations. *Gut Pathog*. 2017;9:76. doi:10.1186/s13099-017-0222-9
39. Ruiz J, Navia MM, Vila J, Gascón J. Prevalence of the *Sat* gene among clinical isolates of *Shigella* spp. causing travelers' diarrhea: geographical and specific differences. *J Clin Microbiol*. 2002;40(4):1565–1566.
40. Andrade FB, Abreu AG, Nunes KO, Gomes TAT, Piazza RMF, Elias WP. Distribution of serine protease autotransporters of Enterobacteriaceae in typical and atypical enteroaggregative *Escherichia coli*. *Infect Genet Evol*. 2017;50:83–86. doi:10.1016/j.meegid.2017.02.018
41. Nezarieh R, Shakibaie MR, Nave HH, Norouzi A, Salajegheh G, Hayatbakhsh M. Distribution of virulence genes, enterotoxin and biofilm formation among enteroaggregative *Escherichia coli* (EAEC) strains isolated from stools of children with diarrhea in South East Iran. *Arch Pediatr Infect Dis*. 2015;3(3):e29745. doi:10.5812/pedinf
42. Guignot J, Chaplais C, Coconnier-Polter MH, Servin AL. The secreted autotransporter toxin, *Sat*, functions as a virulence factor in Afa/Dr diffusely adhering *Escherichia coli* by promoting lesions in tight junction of polarized epithelial cells. *Cell Microbiol*. 2007;9(1):204–221. doi:10.1111/j.1462-5822.2006.00782.x
43. Al-Hasani K, Navarro-Garcia F, Huerta J, Sakellaris H, Adler B. The immunogenic *SigA* enterotoxin of *Shigella flexneri* 2a binds to HEp-2 cells and induces fodrin redistribution in intoxicated epithelial cells. *PLoS One*. 2009;4(12):e8223. doi:10.1371/journal.pone.0008223
44. Hosseini Nave H, Mansouri S, Taati Moghadam M, Moradi M. Virulence Gene Profile and Multilocus Variable-Number Tandem-Repeat Analysis (MLVA) of Enteroinvasive *Escherichia coli* (EIEC) isolates from patients with diarrhea in Kerman, Iran. *Jundishapur J Microbiol*. 2016;9(6):e33529. doi:10.5812/jjm
45. Sabat AJ, Budimir A, Nashev D, et al. Overview of molecular typing methods for outbreak detection and epidemiological surveillance. *Euro Surveill*. 2013;18(4):20380. doi:10.2807/ese.18.04.20380-en
46. Ranjbar R, Tabatabaee A, Behzadi P, Kheiri R. Enterobacterial Repetitive Intergenic Consensus Polymerase Chain Reaction (ERIC-PCR) genotyping of *Escherichia coli* strains isolated from different animal stool specimens. *Iran J Pathol*. 2017;12(1):25–34.

Infection and Drug Resistance**Dovepress****Publish your work in this journal**

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of

antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>